Big UK based drug companies have said they want Britain to remain in the EU, but would exit affect access to medicines? Anne Gulland examines the key questions Anne Gulland journalist, London, UK
If the relationship became more distant the UK may lose access to the single authorisation, meaning an extra regulatory hurdle for drug companies. The BioIndustry Association (BIA), which represents UK biotechnology companies, told the House of Commons inquiry into EU regulation of life sciences that new drugs would probably be launched first in the EU and then in the UK.
1 The UK makes up just 3% of the global market for the biomedical industry, compared with 27% for the EU as a whole, meaning a risk that patients may not get fast access to new medicines According to the Association of the British Pharmaceutical Industry (ABPI) the UK has an important role in initiatives such as the early access to medicines scheme and the adaptive pathways pilot, which allow for early and progressive access to medicines. The UK has chaired all discussions on this-a role it would probably have to give up if it left the EU.
Would it matter if the European Medicines Agency was no longer in London?
In its submission to the science and technology committee the ABPI said that the agency's presence in London gives the UK's Medicines and Healthcare Products Regulatory Agency more clout over regulatory development, both in Europe and around the world.
2 "Colocation with the MHRA has reinforced and further enhanced the engagement and thought leadership that the MHRA plays in European and global regulatory development," the submission said.
According to press reports, Denmark and Sweden are vying with each other to become the agency's home in the event of Brexit-evidence of the benefits of hosting the agency, according to the BIA. The MHRA conducts 30% of approvals for the EMA, making the UK an attractive place for global players to conduct a clinical trial.
"You would look to place that investment in the country where you're going to do the majority of your work. If you're flying in from Boston you would want to fly into just London, rather than flying to London then Frankfurt," says Steve Bates, chief executive of the BIA.
Would big British based drug companies move elsewhere?
The UK's two big drug companies, GlaxoSmithKline and AstraZeneca, have both strongly stated their support for remaining in the EU. However, neither company has indicated that it would seek to move its head office if the UK did leave. In its annual report GSK said Brexit would not have a "material adverse impact" on its results or financial position. 3 Bates says that retaining the companies in the UK matters. "The life science industry is a net exporter and is a massive contributor to the exchequer. If you want an economy delivering some of the things that are likely to be growth businesses for the 21st century it's important to retain the big beasts as well as grow and nurture your start-ups," he says.
Brexit campaigners point to Switzerland, which is not part of the EU or the European Economic Area, as proof of a thriving pharmaceutical sector outside the EU.
But, says David Taylor, professor emeritus of pharmaceutical and public health policy at University College London, Switzerland's tax regime makes it an attractive place to do business. "Switzerland has a much more positive policy towards industry than the UK has. It's much more supportive of Novartis than we are of AstraZeneca," he says. The most common pricing policy in Europe is external reference pricing, whereby countries benchmark each other's prices. But the UK is also a cosignatory of the EU Joint Procurement Agreement, which enables countries to cooperate over procurement in the event of a cross-border health emergency-to stop one country buying up all the relevant vaccines, for example. Some commentators are wondering if it could also be used to negotiate better prices for high cost drugs.
